Evidence map›Paper›PMID 42380524›Full record

ReviewCancer causes & control : CCC2026

Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.

Honghao Yu, Wenzhi Feng, Di Lan, Qianyi Liu, Xia He, Siyu Zhang, Chunyu Tong, Bocui Song

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Honghao YuHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Wenzhi FengHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Di LanHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Qianyi LiuHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Xia HeHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Siyu ZhangHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China.
Chunyu TongHeilongjiang Provincial Key Laboratory of Animal Cell Activities and Stress Adaptations, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China. tongchunyu@126.com.
Bocui SongHeilongjiang Provincial Key Laboratory of Environmental Microbiology and Recycling of Argo-Waste in Cold Region, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, Heilongjiang Province, People's Republic of China. songbocui66@163.com.

Funding

Cultivation Project of Heilongjiang Bayi Agricultural University XDB-2016-22Development of a Recombinant Subunit-Targeted Vaccine for Bovine Mastitis: A Cultivation Project of Heilongjiang Bayi Agricultural University LJGXCG2025-P35Key Research and Development Project of Heilongjiang Province of China GZ20210101Postdoctoral Scientific Research Start-up Fund of Heilongjiang LBH-Q21158
6 · The paper itself

Abstract

Globally, breast cancer remains a leading cause of morbidity in women. Conventional therapies, including surgical intervention, radiation, and chemical treatments, though effective, frequently result in significant adverse effects and toxicity. CAR-T cell therapy represents a novel immunotherapeutic strategy, wherein T cells are genetically modified to precisely target and eradicate malignant cells. The article provides a detailed introduction to the structure and function of CAR-T cells, particularly the improvements in anti-tumor efficacy across different generations of CAR-T cells. Furthermore, the article explores the primary targets of CAR-T cell therapy in the clinical treatment of breast cancer, such as HER2, EGFR, and MUC1, and analyzes the potential and limitations of these targets in therapy. In conclusion, the review outlines significant hurdles in CAR-T cell therapy for breast cancer, such as tumor diversity, the inhibitory tumor milieu, unintended targeting, and cytokine storm, offering strategic solutions to mitigate these obstacles.

Indexed as

Breast NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesFemaleHumansReceptors, Chimeric AntigenBreast cancerCAR-T cell therapyChimeric antigen receptor-T cellsClinical targetsImmunotherapy

Identifiers

PMID42380524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.